The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia
{{output}}
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors a... ...
